Company Profile

Protext Mobility, Inc. is a biotech company developing a hemp/cannabidiol (CBD) - cannabis medicines platform for the legal cannabis industry, using live plant extraction processes and technologies. The Company engages in the research, testing and development of bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications using proprietary live plant extraction technology. The Company's subsidiaries include Plandai Biotechnology, Cannabis Biosciences, Inc., and RSAMMD Acquisitions LLC.

Employees

Sector

Biotechnology & Medical Research

More about the company

08/10/25	Protext Mobility, Inc. Announces J. M. K. Nkosi as Member of Advisory Board	CI
01/11/22	Protext Mobility, Inc and RSAMMDA LLC Provides the Shareholder Update	CI
29/10/21	ProText Mobility, Inc. Provides Updates on Research Conducted At A Licensed Facility	CI
18/01/19	ProText Mobility, Inc. cancelled the acquisition of 60% in Growprocess, Inc.	CI
18/01/18	ProText Mobility, Inc. signed a letter of intent to acquire 60% in Growprocess, Inc.	CI
23/05/17	ProText Mobility, Inc. has Changed its Name to Protext Pharma, Inc	CI
04/05/17	Protext Mobility, Inc. to Conduct Human Clinical Trial with Its Product Phytofare Catechin Complex	CI
26/03/17	ProText Mobility, Inc. acquired Cannabis Biosciences Inc. from Plandaí Biotechnology, Inc. for $0.12 million.	CI
07/03/17	Protext Mobility, Inc. Engages in the Development of Pharmaceutical Applications for the Highly Bioavailable Phytofare®	CI
30/12/16	Plandai SA completed the acquisition of ProText Mobility, Inc. in a reverse merger transaction.	CI
22/12/16	Plandai SA agreed to acquire ProText Mobility, Inc. in a reverse merger transaction.	CI

06-12	Protext Mobility Inc. (OTCID: TXTM) Unveils New Corporate Website and Investor Relations Platform to Support Strategic Growth and Exchange Uplisting	AQ
03-13	ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases	AQ
01-20	Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement	AQ
11-19	Protext Mobility, Inc. (OTC: TXTM) Provides Shareholder Update	AQ
11-17	Protext Mobility, Inc. (OTC: TXTM) Announces Strategic TruLeaf Partnership & Next-Level Innovation	AQ

Manager	Title	Age	Since
Plooy Du Dylon CEO	Chief Executive Officer	-	-
Ahmed Jamaloodeen PSD	President	-	04/09/2001

Director	Title	Age	Since
Ahmed Jamaloodeen CHM	Chairman	-	04/09/2001
Plooy Du Dylon BRD	Director/Board Member	-	04/09/2001

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROTEXT MOBILITY, INC.	-6.67%	-9.68%	-	-	33.41M
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+45.51%	+79.00%	52.1B
ARGENX SE	+0.24%	-1.54%	+53.22%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+3.98%	+423.29%	23.48B
BIONTECH SE	-0.09%	-0.01%	-17.62%	-14.67%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+30.67%	-9.58%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.57%	-30.42%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+306.37%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+26.53%	+636.97%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+24.63%	+191.40%	14.06B
Average	-3.16%	-2.62%	+40.77%	+183.80%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+40.12%	+144.11%

ProText Mobility, Inc. Share Price Other OTC

Stocks

TXTM

US74371E2046

Biotechnology & Medical Research

Latest news : ProText Mobility, Inc.

Press Releases: ProText Mobility, Inc.

Quotes and Performance

Managers and Directors: ProText Mobility, Inc.

Bio Therapeutic Drugs

Company Profile